

PHARMACOEPIDEMIOLOGY AND PRESCRIPTION

J. P. Ottervanger · J. H. P. Wilson · B. H. Ch. Stricker

Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature

Received: 17 February 1997 / Accepted in revised form: 26 May 1997

Abstract *Objectives:* To analyse reports of drug-induced myocardial infarction and chest pain sent to a national reporting centre. To review which drugs were suspected of exhibiting these adverse events and what mechanisms were involved.

Methods: During the 20-year period 1975 through 1994, a total of 19 141 reports on adverse reactions to drugs were received by the Netherlands Centre for Monitoring of Adverse Reactions to Drugs. Of these 19 141 reports, 220 (1.1%) were concerned with drug-induced chest pain or myocardial infarction. After excluding reports in which the causal relationship was unlikely, poorly documented reports and reports on cases of overdose, 183 reports (84%) were analysed.

Results: There were 130 reports (71%) of drug-induced chest pain and 53 reports (29%) of drug-induced myocardial infarction. A total of 104 reports concerned females (57%). The most frequently reported suspected drugs were the antimigraine drug sumatriptan (33 reports, 4 concerning myocardial infarction), the calcium antagonist nifedipin (9 reports, 2 of myocardial infarction) and nicotine [9 reports (8 patches, 1 chewing gum), 5 concerning myocardial infarction]. There were 18 reports of a fatal outcome.

Conclusions: Several drugs can produce chest pain or myocardial ischaemia. It is important to recognise drugs as a potential cause, especially in patients with normal coronary arteries.

Key words Myocardial infarction, Drug induced, Angina pectoris

Introduction

Research on adverse reactions to drugs is an issue of growing professional and public interest. Because serious adverse reactions to drugs are often rare, they are difficult to detect and investigate. In spite of the low incidence, it is important to recognise when drugs are the cause of serious illness. Firstly, if drugs are used for minor ailments, even a low incidence of a serious adverse reaction may unfavourably affect the benefit/risk ratio. Secondly, timely recognition of drugs as the cause of disease and subsequent discontinuation may be life-saving. Finally, knowledge on adverse drug reactions may help to identify groups of patients at particular risk.

The different adverse effects of drugs on the heart are summarised in Table 1. The commonest way in which drugs adversely affect the function of the heart is by the production or aggravation of cardiac arrhythmias or conduction disorders. The next most common adverse effect of drugs on the heart is the initiation or aggravation of heart failure. Less frequently, drugs may cause myocardial ischaemia or infarction or may make the patient more susceptible to these disorders.

Although voluntary reporting systems have several disadvantages, especially under-reporting, they have fundamental value in detecting and characterising rare adverse drug reactions [1, 2]. In this paper, we present an analysis of the reports on drug-induced chest pain and myocardial infarction, received by the Netherlands Centre for Monitoring of Adverse Reactions to Drugs (NARD) between 1 January 1975 and 31 December 1994.

Methods

NARD holds a nationwide voluntary reporting scheme for adverse reactions to drugs. All reports are evaluated by a medical officer and discussed at monthly meetings of the advisory board. All reports received by the NARD between 1 January 1975 and 31 December 1994 concerning drug-induced chest pain, myocardial ischaemia or infarction were included in this study. Only adverse

J.P. Ottervanger · B.H.Ch. Stricker
Netherlands Centre for Monitoring of Adverse Reactions to Drugs

J.P. Ottervanger · J.H.P. Wilson (✉)
Department of Internal Medicine II, University Hospital Dijkzigt,
Dr. Molewaterplein 40, NL-3015 GD Rotterdam, The Netherlands

B.H.Ch. Stricker
Department of Epidemiology and Biostatistics,
Pharmacoeconomics Unit, Erasmus University Medical School,
Rotterdam, The Netherlands

Table 1 Different adverse effects of drugs on the heart

Arrhythmias and conduction disorders
Heart failure
Direct: negative inotropism or chronotropism
Indirect: salt and water retention
Myocardial ischaemia/infarction
Direct: reduced coronary blood flow, thrombosis
Indirect: coronary steal, interaction with anti-anginal drugs
Pericardial disease
Haemopericarditis
Others

drug reactions due to drugs administered in therapeutic doses were considered. All reports came from general practitioners, specialist doctors or hospitals. Minimally requested were data about the age and sex of the patients, dose and duration of use of the suspected drug and clinical signs and symptoms. Each report was evaluated carefully, whereafter the likelihood of a causal relationship was assessed between use of the suspected drug(s) and the symptoms. Evaluation of potential causality of the relationship was based on the temporal relationship of the adverse reaction, pharmacological potential of the suspected drug(s), exclusion of other possible causes of myocardial ischaemia, such as coronary stenoses, and the results of re-exposure (= rechallenge) [3]. A causal relationship was considered 'unclassified' or 'unlikely', respectively, when too few data were available or when more likely causes were found. In the analysis, reports were excluded if the causal relationship was unlikely or unclassified.

Acute myocardial infarction was considered to be present if at least two of the following criteria were present: (1) a recent positive clinical history of chest pain of at least 30 min; (2) characteristic changes in the electrocardiogram; and (3) peak elevation of serum enzymes [creatinine phosphokinase (CPK), serum glutamic oxaloacetic transaminase (SGOT)] of at least twice the upper limit of normal.

Table 2 Overview of drugs which were related to chest pain or myocardial infarction in 183 reports^a. NSAIDs non-steroidal anti-inflammatory drugs

Drug group (number of reports)	Drug (number of reports)
Cardiovascular (37)	
Ca-antagonists (15)	Nifedipine (9), diltiazem (4), verapamil (2)
ACE inhibitors (6)	Captopril (1), lisinopril (2), perindopril (2), enalapril (1)
β-adrenoceptor blockers (5)	Oxprenolol (1), pindolol (1), atenolol (1), metoprolol (2)
α ₁ -adrenoceptor blockers (2)	Urapidil (1), prazosin (1)
Other (9)	Diuretics (7), ibopamine (1), disopyramide (1)
Central nervous system (53)	
Antidepressants (17)	Imipramine (1), amitriptyline (2), mianserin (1), moclobemide (4), fluvoxamine (2), trazodone (2), fluoxetine (3), maprotiline (1), doxepine (1)
Antipsychotics (1)	Clozapine (1)
Anti-migraine (35)	Ergotamine (1), sumatriptan (33), methysergide (1)
Respiratory system (15)	
β-sympatho-mimetics (7)	Salbutamol (3), salmeterol (4), formoterol (2)
Antihistamines (5)	Terfenadine (1), cetirizine (2), cinnarizine (2)
Other (3)	Theophylline (1), beclomethason (1), noscapine (1)
Hormones (12)	Oral contraceptives (4), oestrogens (3), sulprostone (1), epoetin (1), desmopressin (3)
Anti-infectives (15)	
Antibiotics (10)	Nitrofurantoin (4), co-trimoxazole (1), amphotericin (1), amoxicillin (1), metronidazole (1), norfloxacin (1)
Others (6)	Mefloquine (3), niridazol (2), ketoconazol (1)
Analgesics (10)	NSAIDs (6), glafenine (2), penicillamine (1), aspirin (1)
Gastro-intestinal drugs (5)	Cisapride (2), cimetidine (2), domperidon (1)
Miscellaneous (44)	Alfuzosin (3), nicotine (9), amphetamines (2), fenfluramine (2), β-blocker containing eye drops (4), various (24)

^a In nine reports, more than one drug was suspected

Differences between group means were tested by two-tailed Student's *t*-test. A Chi-square statistic was calculated to test differences between proportions. Statistical significance was defined as a *P* value of less than 0.05.

Results

NARD received, during the study period, a total of 19 141 reports on adverse reactions to drugs. Of these reports, 220 (1.1%) concerned reports of drug-induced chest pain or myocardial infarction. Twenty-two reports (10%) were poorly documented and in 15 reports (6.8%), the causal relationship was unlikely. The poorly documented reports and the reports in which the causal relationship was unlikely were excluded from further analysis. Three reports, on myocardial infarction to sumatriptan, nicotine and sulprostone, respectively, have previously been reported in the literature as a case-report [4].

The 183 reports, which were suitable for analysis, concerned 103 females (56%) and 80 males (44%), with an average age of 51 years. There were 130 reports (71%) of drug-induced chest pain and 53 reports (29%) of drug induced myocardial infarction. Of the 130 patients with chest pain attributed to use of drugs, 40 patients (31%) had a positive rechallenge after renewed exposure to the drug. Compared with drug-induced chest pain, drug-induced myocardial infarction was more frequently reported in males (63 vs 35%; *P* < 0.001). Eighteen patients (9.8%) died after myocardial infarction. Age was not related to myocardial

infarction or death. Only in a few patients with drug-induced chest pain was an ECG performed, but, by the time this was done, in almost every patient the chest pain had already disappeared. In six patients abnormal ECGs were observed.

In 174 out of 183 reports, one drug was suspected to have caused the adverse reaction, whereas in five reports, two drugs were suspected and in four reports, more than two drugs were suspected. Chest pain or myocardial infarction were attributed to a total of 98 different drugs (Table 2). The drugs most frequently reported were sumatriptan (33 reports), nicotine (9 reports), nifedipine (9 reports), diltiazem (4 reports), moclobemide (4 reports) and salmeterol (4 reports).

There were several reports of chest pain or myocardial infarction attributed to the use of cardiovascular drugs. Fifteen reports concerned calcium-channel blocking agents: nine reports concerning nifedipine (seven chest pain, two acute myocardial infarction), four reports concerning diltiazem (all chest pain) and two reports concerning chest pain attributed to use of verapamil. There were three reports of chest pain induced by systemic use of β -adrenoceptor blockers (oxprenolol, pindolol and atenolol). ACE inhibitors were suspected in five reports: captopril (one report of chest pain), lisinopril (one report of chest pain, one report of myocardial infarction) and perindopril (one report of chest pain, one report of myocardial infarction).

There were 17 reports of chest pain or myocardial infarction attributed to the use of antidepressants. Three of them concerned fatal myocardial infarction after use of tricyclic antidepressants (one imipramine, two amitriptyline). Of four reports concerned with myocardial infarction attributed to use of the monoamine oxidase (MAO)-A inhibitor moclobemide, two concerned a fatal reaction.

Several reports concerned chest pain or myocardial infarction attributed to drugs for respiratory problems, of which seven reports concerning β -sympatho-mimetics are of special interest.

Four reports concerned adverse reactions attributed to use of oral contraceptives (two myocardial infarction, two chest pain), whereas in three reports, chest pain or myocardial infarction was attributed to other oestrogens. One report concerned a myocardial infarction due to intravenous administration of sulprostone. Three reports concerned chest pain (one report) or myocardial infarction (two reports) attributed to desmopressin.

Discussion

The most common cause of myocardial ischaemia is coronary artery sclerosis and stenosis, whereas an acute myocardial infarction is mostly caused by occlusive thrombi in atherosclerotic coronary arteries. Transmural myocardial infarction with angiographically normal coronary arteries is rare [5] and has been associated with a defect of fibrinolysis [6], early age [7], cigarette

smoking [8] and drug use. Especially in patients with chest pain or myocardial infarction and normal coronary arteries, it is important to consider drugs as a potential cause of the complaints.

Although the incidence of acute myocardial infarction due to drug-induced ischaemia is probably low, there are several reasons why it is important to know which drugs can induce myocardial ischaemia and what mechanism is involved. Firstly, drugs which should be used cautiously can be identified, especially in patients with coronary artery disease. Secondly, it is important to consider a drug adverse event if chest pain occurs in a patient using some specific drugs, particularly if it is a patient without any reason to suspect a cardiac origin of the complaints, for example a young female. Under certain circumstances, discontinuation of a specific drug may prevent myocardial infarction and may be life-saving. Thirdly, in patients diagnosed as having myocardial infarction or angina pectoris with normal coronary angiography, the possibility of an association with the intake of some drugs should be considered. Fourthly, the diagnostic and therapeutic approach of patients with drug-induced myocardial ischaemia or infarction may differ from patients with regular myocardial ischaemia or infarction. Finally, the pharmacological mechanisms may also provide insight into the pathophysiology of 'not-drug-induced' myocardial ischaemia.

It is, of course, important to remember that our reports of chest pain or myocardial infarction concern rare adverse reactions, and that the risk-benefit assessment of a specific drug can be only assessed in a (randomised) clinical trial.

Cardiovascular drugs

There were several reports of chest pain or myocardial infarction after use of cardiovascular drugs. Especially interesting were 15 reports of chest pain or myocardial infarction attributed to calcium-antagonists. Recently, in a case-control study of hypertensive patients, a relatively higher risk for myocardial infarction was found in patients taking calcium antagonists [9]. In a meta-analysis by Furberg et al., a dose-dependent association of use of nifedipine with mortality was observed [10]. Since hypertension is associated with both myocardial infarction and mortality, these associations are explained by some as a result of confounding by indication [11]. Confounding by indication can even result in a dose-dependent association. There are, however, several case-reports in which a relationship between administration of nifedipine and aggravation of myocardial ischaemia was observed [12, 13].

There were three reports of chest pain induced by systemic use of β -adrenoceptor blockers (oxprenolol, pindolol and atenolol), and four reports of chest pain induced by β -adrenoceptor blocker-containing eye drops (timolol 2x, betaxolol, metipranolol). Acute myocardial infarction has been associated with propranolol [14] and

metoprolol [15]. Also β -blocker-containing eye drops have been associated with chest pain [16] and myocardial infarction [17]. The pathophysiological mechanism of β -adrenoceptor blocker-induced myocardial ischaemia is probably coronary vasospasm mediated by α -adrenoceptors [15].

A few reports concerned chest pain or myocardial infarction attributed to the use of ACE inhibitors. In the literature, several case reports of angina pectoris related to captopril have been published [18, 19].

Central nervous system

There were three reports of fatal myocardial infarction attributed to tricyclic antidepressants. This is especially of interest because, recently, in a case-control study, an unexpected six fold increase in risk of fatal myocardial infarction, associated with current use of tricyclic antidepressants was demonstrated in young women [20]. In general, the cardiovascular effects of tricyclic antidepressants are considered to consist mainly of conduction disturbances, arrhythmias and orthostatic hypotension [21, 22]. Myocardial infarction was attributed to moclobemide in four reports. Recently, hypertension was described as an adverse reaction to this MAO-A inhibitor [23].

Anti-migraine drugs

In the literature, there have been several reports of cardiac ischaemia due to the antimigraine drugs ergotamine [24, 25], methysergide [26], sumatriptan [27] and isometheptene [28]. The proposed mechanism is coronary spasm. There was a large number of reports sent to our centre of chest pain (29 reports) and several reports (four) of myocardial infarction attributed to the use of the new anti-migraine drug sumatriptan. One report of myocardial infarction [29] and 13 reports of chest pain [30] were previously published in the literature as case reports. In clinical trials, the frequency of chest pain after use of sumatriptan was approximately 5% [31, 32], whereas in a postmarketing study, the frequency was estimated to be 8% [33]. Furthermore, several cardiac adverse reactions associated with use of sumatriptan have been reported in the literature [27, 34, 35]. It is, however, not yet known whether the frequency of cardiac adverse reactions to sumatriptan is more frequent than to ergotamine.

Respiratory system

There were six reports of myocardial infarction and one report of chest pain attributed to use of β -sympathomimetics and one report of myocardial infarction attributed to theophylline. In the literature, acute myocardial infarction following both intravenous and inhaled treatment with salbutamol has been described

[36, 37]. An increase of mortality in regular users of β_2 -adrenoceptor agonists has been demonstrated, but drug-induced myocardial ischaemia is not considered to be one of the mechanisms [38]. A case report of a patient who experienced a myocardial infarction attributed to use of theophylline was previously published [39]. Furthermore, it has been demonstrated that theophylline can cause tachycardia and myocardial ischaemia, even at the recommended doses [40]. However, since cardiac and respiratory disease commonly co-exist (and have several risk factors in common, such as smoking) the causal implications remain difficult to assess.

Hormones

There were two reports of myocardial infarction during use of oral contraceptives. In fact, this potential association cannot be clarified by case reports, since there is a lack of clear temporal relationship. In a case-control study, Thorogood et al. demonstrated that current users of oral contraceptives had an increased, although not statistically significant, risk of fatal myocardial infarction [41]. A more recently published study demonstrated a reduced risk of myocardial infarction in users of third-generation oral contraceptives [42].

In two reports of myocardial infarction and in one report of chest pain, the reactions were attributed to use of desmopressin. This association has previously been described in the literature [43].

Analgesics

Coronary spasm has been described after administration of naproxen (44) and glafenine (45): the proposed mechanism is an allergic reaction [44].

Miscellaneous

Of the reports of chest pain ($n = 4$) or myocardial infarction ($n = 5$) attributed to use of nicotine sent to the national centre one had previously been published as a case report [46]. There have been reports of serious cardiovascular adverse reactions in the literature, including acute myocardial infarction and cardiac arrest, associated with continued smoking during use of the patches [47–49].

There were two reports of acute myocardial infarction and one report of chest pain attributed to the use of alfuzosin. Alfuzosin is a relatively new drug, used for the symptomatic treatment of benign prostatic hyperplasia, which acts as an antagonist of α_1 -adrenoceptors [50]. According to the close temporal relationship with intake of alfuzosin, the relationship between use of this drug and the adverse reactions seems to be probable. Alfuzosin is, however, often prescribed to patients with a high risk of coronary diseases (elderly males). There

were also reports concerning chest pain attributed to two other α_1 -adrenoceptor blockers, urapidil and prazosin, used for treatment of hypertension.

Two reports also concerned chest pain attributed to use of fenfluramine. Myocardial infarction associated with dexfenfluramine has been described previously [51].

Underreporting and selective reporting

The most important disadvantages of a spontaneous reporting system are under-reporting and selective reporting. According to the latter, it is particularly interesting that chest pain or myocardial infarction was not even in one report attributed to cytostatic drugs, blood coagulation factors or cocaine.

Malignancy may affect the heart by direct invasion, as in lymphoma or by blood-borne metastases, as in malignant melanoma [52]. Moreover, several antiproliferative drugs and/or irradiation to the mediastinum can cause cardiac damage [53–55]. These drugs include 5-fluorouracil [56], taxol [57], bleomycin and etoposide [58] and cisplatin [59].

Several cases of myocardial infarction attributed to the administration of blood coagulation factors have been documented in the literature [60–62]. In most cases, patients with haemophilia were involved.

Cases of cocaine-induced myocardial infarction were previously reviewed in the literature [63].

In conclusion, the present study, the reports of drug-induced chest pain or myocardial infarction as reported to the NARD during the period 1975 through 1994 were demonstrated. The reviewed reports give an impression of the different drugs and the different mechanisms in the difficult field of drug-induced myocardial ischaemia or infarction.

References

- Rawlins MD (1988) Spontaneous reporting of adverse drug reactions I: the data, II: uses. *Br J Clin Pharmacol* 26: 1–11
- Venning GR (1983) Identification of adverse reactions to new drugs. *BMJ* 286: 289–292
- Stricker BHC (1989) Side effects of drugs: assessment of causality. *Ned Tijdschr Geneesk* 133: 275–280
- Fliers E, Dueren DR, van Zwieten PA (1991) A prostaglandin analogue as a probable cause of myocardial infarction in a young woman [letter]. *BMJ* 302: 416
- Raymond R, Lunch J, Underwood D, leatherman J, Razavi M (1988) Myocardial infarction and normal coronary arteriography: a 10 year clinical and risk analysis of 74 patients. *J Am Coll Cardiol* 11: 471–477
- Verheugt FWA, Cate JW ten, Sturk A, Imandt L, Verhorst PM, Eenige MJ van, Verwey W, Roos JP (1987) Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. *Am J Cardiol* 59: 1075–1079
- Rosenblatt A, Selzer A (1977) The nature and clinical features of myocardial infarction with normal coronary arteriogram. *Circulation* 55: 578–581
- McKenna Wj, Chew CYC, Oakley CM (1980) Myocardial infarction with normal coronary angiogram (possible mechanism of smoking risk in coronary artery disease). *Br Heart J* 43: 493–498
- Psaty BN, Heckbert SR, Koepsall TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. *JAMA* 274: 620–625
- Furberg CD, Psaty BM, Meyer JV. Nifedipine (1995) Dose-related increase in mortality in patients with coronary heart disease. *Circulation* 92: 1326–1331
- Buring JE, Glynn RJ, Hennekens CH (1995) Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. *JAMA* 274: 654–655
- Jariwalla AG, Anderson EG (1978) Production of ischaemic cardiac pain by nifedipine. *BMJ* 1: 1181–1182
- Sia STB, MacDonald PS, Triester B, Oliver LE, Horowitz JD, Goble AJ (1985) Aggravation of myocardial ischaemia by nifedipine. *Med J Aust* 142: 48–50
- Millar AB (1982) Myocardial infarction during asthmatic attack induced by ingestion of propranolol. *J R Soc Med* 75: 661–662
- Nanas JN, Sutton RB, Alazraki N, Tsagaris TJ (1987) Acute myocardial infarction in post infarct patient possibly through beta blocker-induced coronary artery spasm. *Am Heart J* 113: 388–391
- Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kiritky JN (1986) Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. *Am J Ophthalmol* 102: 606–611
- Chamberlain TJ (1989) Myocardial infarction after ophthalmic betaxolol. *N Engl J Med* 321: 1342
- Davis JB (1988) Chest pain after captopril. *BMJ* 296: 214
- Baker KM, Johns DW, Ayers CR, Carey R (1980) Ischaemic cardiovascular complications concurrent with administration of captopril. *Hypertension* 2: 73–74
- Thorogood M, Cowen P, Mann J, Murphy M, Vessey M (1992) Fatal myocardial infarction and use of psychotropic drugs in young women. *Lancet* 340: 1067–1068
- Halper JP, Mann JJ (1988) Cardiovascular effects of antidepressant medications. *Br J Psychiat* 153 [suppl 3]: 87–98
- Rudorfer MV, Potter WZ (1989) Antidepressants; a comparative review of the clinical pharmacology of the “newer” versus the “older” drugs. *Drugs* 37: 713–738
- Coulter DM, Pillans PI (1995) Hypertension with moclobemide. *Lancet* 346: 1032
- Klein LS, Simpson RJ Jr, Stern R, Hayward JC, Foster JR (1982) Myocardial infarction following administration of sublingual ergotamine. *Chest* 82: 375–376
- Snell NJ, Russel-Smith C, Coysh HL (1978) Myocardial ischaemia in migraine sufferers taking ergotamine. *Post Med J* 54: 37–39
- Hudgson P, Foster JB, Walton JN (1967) Methysergide and coronary-artery disease. *Lancet* 1: 444–445
- Ottervanger JP, Stricker BHC (1995) Cardiovascular adverse reactions to sumatriptan: cause for concern? *CNS Drugs* 3: 90–98
- George S, Vannozi R (1993) Myocardial infarction induced by migraine therapy. *Ann Emerg Med* 25: 718–719
- Ottervanger JP, Paalman HJA, Boxma GL, Stricker BHC (1993) Transmural myocardial infarction with sumatriptan. *Lancet* 341: 861–862
- Stricker BHC (1992) Coronary vasospasm and sumatriptan. *BMJ* 305: 118
- Brown EG, Endersby CA, Smith RN, Talbot JCC (1991) The safety and tolerability of sumatriptan: an overview. *Eur Neurol* (1991) 31: 339–344
- Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. *Lancet* 346: 923–926
- Ottervanger JP, Van Witsen TB, Valkenburg HA, Stricker BHC (1994) Adverse reactions attributed to sumatriptan: a

- postmarketing study in general practice. *Eur J Clin Pharm* 47: 305–309
34. Kelly KM (1995) Cardiac arrest following use of sumatriptan. *Neurology* 45: 1211–1213
 35. Walton-Shirley M, Flowers K, Whiteside JH (1995) Unstable angina pectoris associated with Imitrex therapy. *Cathet Cardiovasc Diagn* 34: 188
 36. Santo M, Sidi Y, Pinkhas Y (1980) Acute myocardial infarction following intravenous salbutamol. *S Afr Med J* 80: 394
 37. Shovlin CL, Tam FWK (1990) Salbutamol nebuliser and precipitation of critical cardiac ischaemia. *Lancet* 336: 1258
 38. Sears MR, Taylor DR (1994) The β_2 -agonist controversy. Observations, explanations and relationship to asthma epidemiology. *Drug Safety* 11: 259–283
 39. Raggi P (1994) Therapeutic theophylline levels and adverse cardiac events. *Ann Int Med* 120: 891
 40. Bittar G, Friedman HS, Dominguez A, Voperian V (1991) Theophylline produces an adverse effect on myocardial lactate metabolism at a therapeutic blood concentration: an effect blocked by verapamil. *J Pharmacol Exp Ther* 257: 214–218
 41. Thorogood M, Mann JI, Murphy M, Vessey M (1991) Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. *Br J Obstet Gynaecol* 98: 1245–1253
 42. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R, Thorogood M (1996) Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. *BMJ* 312: 88–90
 43. McLeod BC (1990) Myocardial infarction in a blood donor after administration of desmopressin. *Lancet* 336: 1137–1138
 44. Cisteró C, Uriás S, Guindo J, Leonart R, Garcia-Moll M, Geli A, Bayes de Luna A (1992) Coronary artery spasm and acute myocardial infarction in naproxen-associated anaphylactic reaction. *Allergy* 47: 576–578
 45. Weber S, Genevray B, Pasquier G, Chapsal J, Bonnin A, Degeorges M (1982) Severe coronary spasm during drug-induced immediate hypersensitivity. *Lancet* 2: 821
 46. Ottervanger JP, Festen JM, Vries de AG, Stricker BHC (1995) Acute myocardial infarction while using the nicotine patch. *Chest* 107: 1765–1766
 47. Hwang SL, Waldholt M (1992) Heart attacks reported in patch users still smoking. *The Wall Street Journal*:B1, June 19
 48. Dacosta A, Guy JM, Tardy R, Gonther R, Denis L, Lamaud M, Cerisier A, Verneyre H (1993) Myocardial infarction and nicotine patch: a contributing or causative factor? *Eur Heart J* 14: 1709–1711
 49. Warner Jr JG, Little WC (1994) Myocardial infarction in a patient who smoked while wearing a nicotine patch. *Ann Intern Med* 120: 695
 50. Wilde MI, Fitton A, McTavish D (1993) Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. *Drugs* 45: 410–429
 51. Bain SC, Rowe BR (1990) Myocardial infarction associated with the use of dextrofenfluramine. *BMJ* 301: 345
 52. Roberts W, Glancy DL, DeVita V Jr (1968) Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). A study of 196 autopsy cases. *Am J Cardiol* 22: 68
 53. House KW, Simon SR, Pugh RP (1991) Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease. *Clin Cardiol* 15: 122–125
 54. Tenet W, Missri J, Hager D (1986) Radiation-induced stenosis of the left main coronary artery. *Cathet Cardiovasc Diagn* 12: 169–171
 55. Radwaner BA, Geringer R, Goldmann AM, Schwartz MJ, Kemp HG (1987) Left main coronary artery stenosis following mediastinal irradiation. *Am J Med* 82: 1017–1020
 56. Labianca R, Luporini G (1991) 5-fluorouracil cardiotoxicity: the risk of rechallenge. *Ann Oncol* 2: 383
 57. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC (1991) Cardiac disturbances during the administration of taxol. *J Clin Oncol* 9: 1704–1712
 58. Schwarzer S, Eber B, Greinix H, Lind P (1991) Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. *Eur Heart J* 12: 748–750
 59. Talcott JA, Herman TS (1987) Acute ischemic vascular events and cisplatin [letter]. *Ann Int Med* 107: 121–122
 60. Chavin SI, Siegel DM, Rocco TA Jr, Olson JP (1988) Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. *Am J Med* 85: 245–249
 61. Schimpf K, Zeltsch C, Zeltsch P (1982) Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A [letter]. *Lancet* 2: 1043
 62. Mizon P, Goudemand J, Jude B, Marey A (1992) Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. *Ann Hematol* 64: 309–311
 63. Hollander JE, Hoffmann RS (1992) Cocaine-induced myocardial infarction: an analysis and review of the literature. *J Emerg Med* 10: 169–177